Besides, we forecasted the potential compounds targeting CDKN1C and DLK1 in T2DM, providing a theoretical basis for future studies on the mechanisms of T2DM progression and the exploitation of innovative therapies in future. This evidence concerns the gene CDKN1C and type 2 diabetes mellitus.